Next Generation Sequencing (NGS) Market Worth $8.7 Billion by 2020
The “Next Generation Sequencing (NGS) Market by Platforms (Illumina HiSeq, MiSeq, HiSeqX Ten, NextSeq 500,Thermo Fisher Ion Proton/PGM), Bioinformatics (Exome Sequencing, RNA-Seq, ChIP-Seq), Technology (SBS, SMRT) & by Application (Diagnostics, Personalized Medicine) – Global Forecast to 2020”, analyzes and studies the major market drivers, restraints, and opportunities in North America, Europe, Asia and Rest of World.
Dallas, TX -- (SBWire) -- 05/25/2015 --Browse 130 market data tables with 52 figures spread through 242 pages and in-depth TOC on "Next Generation Sequencing (NGS) Market".
Early buyers will receive 10% customization on this report.
This report studies the global NGS market over the forecast period of 2014-2020.
The global NGS market will be worth $2.5 billion by the end of 2014 and is poised to reach $8.7 billion by 2020 at a CAGR of more than 20.0%. The growth of the overall NGS market is driven by continuous innovations and developments in the market aimed at higher throughput, increased accuracy, and affordable costs. The cost for whole genome sequencing has reached the much awaited $1,000 mark as claimed by the market leader Illumina. The opportunities for the growth of this market include developments in pre-sequencing, cloud computing, and NGS bioinformatics solutions. However, factors such as high reliability on grants and funding from the government and decrease in capital expenditure from academic institutions are hindering the growth of the market. In addition, the interpretation of big data generated by sequencers and the subsequent storage and management of analyzed data is still a challenge. Owing to the complexity of NGS technologies and data, standardization of the overall NGS workflow is still an unmet need.
Inquiry before Buying: http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=546
This research report categorizes and analyzes the global NGS market on the basis of steps in the NGS workflow, NGS technologies, and NGS applications. All these markets are further divided into segments and sub-segments, to provide exhaustive value analysis for the years 2012, 2013, 2014 and forecast to 2020. Based on the NGS workflow, NGS pre-sequencing, sequencing and data analysis form the overall NGS market. Under pre-sequencing, the solutions for sample preparation are covered. The sequencing market covers platforms, reagents and services from key players like Illumina (U.S.), Life Technologies (Thermo Fisher scientific) (U.S.), 454 Roche (U.S.), and Pacific Biosciences (U.S.). The market for sequencing platforms has been very dynamic. Some revolutionary platforms like GA IIx (Illumina) and SOLiD Series (Life Technologies) will take a setback and newer platforms like HiSeq X Ten, NextSeq 500, MiSeq and Ion Torrent Proton will gain market dominance.
The NGS data analysis market includes the market by product (software and services) and by applications such as whole genome sequencing, exome sequencing, targeted re-sequencing, de novo sequencing, RNA-Seq, ChIP-Seq and Methyl-Seq. Some of the major applications of NGS include diagnostics, drug discovery, biomarker discovery, personalized medicine, and agriculture and animals research. Each market is comprehensively analyzed at a granular level by geography (North America, Europe, Asia, and Rest of the World) to provide in-depth information on the global scenario.
You can speak To Research Analyst to know more about Report:
North America is poised to account for the largest market share of the NGS market, followed by Europe, in 2014. However, Asia presents significant opportunities for investors as the developed markets get saturated.
The NGS platforms market is a consolidated one and will be dominated by Illumina in 2014, which accounted for the largest market share of more than 70%. Other companies with commercial platforms include Life Technologies (Thermo Fisher Scientific) (U.S.), 454 Roche (U.S.), and Pacific Biosciences (U.S.). The NGS bioinformatics/data analysis market is highly fragmented with key players like CLC bio (Denmark) (A member of QIAGEN), Biomatters (New Zealand), Partek (U.S.), Genomatix (Germany), Knome (U.S.) and DNASTAR (U.S.) dominating this market space.
MarketsandMarkets is world's No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.
M&M's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.
Subscribe Reports from Healthcare Domain
North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas, TX 75252
Visit MarketsandMarkets Blog @ http://mnmblog.org/market-research/healthcare/biotechnology
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets
Media Relations Contact
View this press release online at: http://rwire.com/600095